Codes ATC:
A02BA02
EMLc
Indication
Peptic ulcer, site unspecified
Code ICD11:
DA61
INN
Ranitidine
Type de médicament
Chemical agent
Type de liste
Liste de base
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
Des médicaments appartenant à la même classe pharmacologique peuvent être utilisés
Limites de l'équivalence thérapeutique
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Limites d'équivalence thérapeutique pour l'EMLc
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Wikipédia
DrugBank
Résumé des preuves et recommandation du comité d'experts
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.